APA

Take a look at innovative GSK-3β inhibitors to enhance efficacy and reduce adverse effects seen in lithium with Jonathan M. Meyer, MD, DLFAPA, at the 2025 APA Annual Meeting.

How many apps do you use on your phone? John Luo, MD, a technology expert shares his thoughts on their usefulness at the 2025 APA Annual Meeting.

Ketamine-assisted psychotherapy: enhancing healing through emotional support and insight-driven therapy for depression.

Psychiatry must embrace media to combat misinformation, shared Mena Mirhom, MD, FAPA, at the 2025 APA Annual Meeting.

Will AI replace psychiatrists and mental health clinicians? John Luo, MD, thinks not, despite the many technological advances of today.

Badr Ratnakaran, MBBs, highlights the rising stressors for older adults, emphasizing the urgent need for improved health care and support systems.

Fathers share their heartbreaking stories of loss and advocate for a new model of suicide prevention that emphasizes early intervention and awareness at the 2025 APA Annual Meeting.

Discover how insulin influences mood and cognition, revealing new therapeutic possibilities for depression and bipolar disorder, in this discussion with Roger McIntyre, MD, FRCPC, at the 2025 APA Annual Meeting.

Experts discuss groundbreaking insights on ketamine's role in treating depression, highlighting its rapid effects and potential to transform psychopharmacology.

Why was this year's APA Annual Meeting historic? H. Steven Moffic, MD, shares his thoughts.

How does adult ADHD differ from pediatric ADHD? Jeffrey Newcorn, MD, shared his expertise at the 2025 APA Annual Meeting.

The APA Annual Meeting: a valuable career opportunity.

At the APA Annual Meeting, John Luo, MD, discussed the importance of managing your online reputation and privacy in today's digital landscape for future opportunities.

Antipsychotic plasma levels play a critical role of in treatment decisions. Learn more in this conversation from the 2025 APA Annual Meeting.

Although there are topics in psychiatry that not exciting, Dr Ghaemi sees plenty of opportunities.

Mena Mirhom, MD, the Psychiatric Times Media & Psychiatry Section Editor, discusses media training for psychiatry fellows, enhancing their skills to effectively communicate and combat misinformation.

Poster presented at the APA Annual Meeting finds zuranolone effective for anhedonia associated with PPD.

Dr Nassir Ghaemi explores the long-term effects and safety of serotonin reuptake inhibitors, revealing benefits and potential risks.

Ramaswamy Viswanathan, MD, DrMedSc, emphasizes the vital role of lifestyle in mental health treatment and advocates for holistic approaches to prevent premature death at the 2025 APA Annual Meeting.

A nonprofit aims to support clinicians and patients with insurance coverage for evidence-based medicine.

Badr Ratnakaran, MBBS, highlights the growing loneliness epidemic and emphasizes its severe impact on mental and physical health at the 2025 APA Annual Meeting.

Resilience: how does it improve overall health? Helen Lavretsky, MD, shared her thoughts at the 2025 APA Annual Meeting.

Promising results from a phase 2 study of CPL'36, a novel PDE10A inhibitor, for acute schizophrenia exacerbation was presented at the APA annual meeting.

Research from the 2025 APA Annual Meeting reveals a strong link between borderline personality disorder and problematic internet use, highlighting impulsivity and compulsivity in affected individuals.

Attendees at the 2025 APA Annual Meeting are excited to connect with peers and experts, exploring lifestyle medicine and networking opportunities for career growth.

Mental health professionals recognize the profound impact of climate change on anxiety, depression, and overall well-being, urging proactive support for affected patients, says one APA attendee.

Angelo Chaia, MD, explores the impact of long-acting injectables on patients with severe mental illness and substance use disorders at the 2025 APA Annual Meeting.

At the APA Annual Meeting, Dana Hilt, MD, PhD, explores the notion of precision psychiatry in depression treatment.

Amir Meftah, MD, discusses the possibility of GLP-1s for addressing metabolic issues associated with antipsychotics.

Dana Hilt, MD, PhD, discusses data on Xanamem’s impact on cortisol and its potential use in MDD at the APA Annual Meeting.